Table 1.
N = 173 (%) | |
---|---|
Age (median, range) |
57 (34–88) |
SEX |
|
Male |
116 (67) |
Female |
57 (33) |
RACE |
|
African American |
90 (52) |
White |
83 (48) |
Performance status (PS) |
|
0-1 |
130 (76) |
2-4 |
42 (24) |
Histology |
|
Adenocarcinoma |
91 (52) |
Non-adenocarcinoma |
82 (47) |
Number of metastatic sites |
|
1-2 |
93 (54) |
>2 |
80 (46) |
Chemotherapy |
|
No chemo |
59 (34) |
Any chemo |
114 (66) |
First response assessment |
|
Response to chemotherapy |
41 (23) |
Stable disease |
24 (14) |
Progression |
39 (23) |
Decline in performance status |
69 (40) |
Survival (months) |
|
Median progression free survival |
3.7 |
Median overall survival | 5.1 |
NSCLC: Non-small cell lung cancer.